Answers are grounded in this paper and cite their sources.
AIM: To study the effects of daidzein on human pancreatic cancer cells in vitro. METHODS: Human estrogen-receptor (ER)-positive pancreatic cancer cells MiaPaCa-2 and ER-negative pancreatic cancer cells PANC-1 were treated by 0.1 micromol/L, 1 micromol/L, 10 microL, 25 microL, 50 microL, 75 microL and 100 microL of daidzein, respectively. Its antiproliferative effect was studied by MTT assay. RESULTS: Daidzein inhibited the growth of MiaPaCa-2 and PANC-1 cells at the concentrations from 0.1 microL to 100 microL. A dose- and time-dependent manner was found. The IC(50) of daidzein on MiaPaCa-2 and PANC-1 cells was 45 microL and 75 micro, respectively. After MiaPaCa-2 cells were treated by daidzein for 3 d and at the concentrations more than IC(50), the inhibitory manner was identical and the inhibition appeared a saturation phenomenon, but the inhibitory manner of daidzein on PANC-1 cells was different from that of MiaPaCa-2 cells. CONCLUSION: Daidzein has antiproliferative effects on human estrogen-receptor-positive and negative pancreatic cancer cells, but their mechanisms may be different.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: